ICLR Q3 2026 Earnings Results — ICON Public Limited Company
NASDAQ · Healthcare · Medical - Diagnostics & Research
Updated
When is ICLR's next earnings date?
ICON Public Limited Company (ICLR) has not announced its next earnings date yet. Its most recent earnings report was on Tuesday, October 27, 2026.
How did ICLR do in its last earnings report?
In its most recent report on Oct 27, 2026 (Q3 2026), ICON Public Limited Company posted EPS of $2.66 versus the $2.62 estimate, a beat of 1.5%. Revenue was $2.02B against a $2.01B estimate. The stock's 1-day post-earnings move was +17.0%.
How much does ICLR stock move after earnings?
ICLR beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 11.0% (up or down) in the day after earnings.
About ICON Public Limited Company
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
🤖 AI Earnings Analysis
ICON’s CRO results are mixed: Q3 EPS of $2.66 beat by $0.04, but fell from $3.31 year over year; revenue was $2.0B, while full-year guidance remains $7.8–8.2B revenue and $10–11 EPS.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-27 | Q3 2026 | 2.62 | 2.66 | +1.53% | $2.02B | ✅ Beat | +17.04% | — | — |
| 2026-07-29 | Q2 2026 | 2.49 | 2.56 | +2.81% | $2.06B | ✅ Beat | -7.10% | -8.23% | -4.75% |
| 2026-06-23 | Q1 2026 | 2.50 | 2.50 | +0.00% | $2.03B | ➖ Inline | +10.86% | +21.76% | +19.38% |
| 2026-05-27 | Q4 2025 | 3.05 | 2.52 | -17.38% | $2.11B | ❌ Miss | +15.49% | +21.49% | +43.40% |
| 2025-10-22 | Q3 2025 | 3.23 | 3.31 | +2.48% | $2.04B | ✅ Beat | -6.54% | -13.84% | -17.90% |
| 2025-04-30 | Q1 2025 | 3.08 | 3.19 | +3.57% | $2.00B | ✅ Beat | -4.11% | -8.31% | -13.97% |
| 2024-10-23 | Q3 2024 | 3.84 | 3.35 | -12.76% | $2.03B | ❌ Miss | -21.03% | -18.83% | -24.22% |
| 2024-07-24 | Q2 2024 | 3.68 | 3.75 | +1.90% | $2.12B | ✅ Beat | -5.63% | -1.00% | -3.45% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q4 FY12 · $829.5M total
| Segment | Share | Revenue | YoY | Q3 FY12 | Q4 FY12 |
|---|---|---|---|---|---|
| Clinical Research | 92.3% | $766.0M | +242.1% | $261.5M | $766.0M |
| Central Laboratory | 7.7% | $63.5M | +240.1% | $24.0M | $63.5M |
By region
Q4 FY23 · $3.65B total
| Segment | Share | Revenue | YoY | Q1 FY22 | Q2 FY22 | Q3 FY22 | Q4 FY22 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 43.6% | $1.59B | +97.3% | $970.6M | $894.0M | $903.2M | $806.8M |
| IRELAND | 34.8% | $1.27B | +115.8% | $367.4M | $501.0M | $526.9M | $589.4M |
| Rest Of Europe | 21.6% | $786.8M | +133.9% | $456.1M | $428.4M | $397.5M | $336.4M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.